Skip to content
10-K

Annual Report

TEVA PHARMACEUTICAL INDUSTRIES LIMITED TEVA TEVJF

0001193125-25-020826

← back to feed
Filed
Feb 5, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Dec 31, 2024 1.13B sh
Stockholders Equity FY 2024 · Dec 31, 2023 $7.51B
Current Liabilities FY 2024 · Dec 31, 2023 $12.25B
Total Liabilities FY 2024 · Dec 31, 2023 $35.35B
Current Assets FY 2024 · Dec 31, 2023 $12.49B
Total Assets FY 2024 · Dec 31, 2023 $43.48B
Shares Diluted FY 2024 · Dec 31, 2022 1.11B sh
Operating Cash Flow FY 2024 · Dec 31, 2022 $1.59B
Cash And Equivalents FY 2024 · Dec 31, 2022 $2.8B
Eps Diluted restated FY 2024 · Dec 31, 2022 −$2.20
Eps Basic restated FY 2024 · Dec 31, 2022 −$2.20
Sga Expense FY 2024 · Dec 31, 2022 $1.18B
Net Income restated FY 2024 · Dec 31, 2022 −$2.45B
Operating Income restated FY 2024 · Dec 31, 2022 −$2.2B
Gross Profit FY 2024 · Dec 31, 2022 $6.97B
Cost Of Revenue FY 2024 · Dec 31, 2022 $7.95B
Revenue FY 2024 · Dec 31, 2022 $14.93B